NCNA NuCana Corp Earnings per share for the last twelve months

NCNA (NuCana PLC) - company brandmark

ProTide technology provides NuCana plc (NCNA) with significant pricing power by targeting resistant tumors. This GURU.Markets 12-month net income per share chart, where the value -3.54 corresponds to the current metric, illustrates profitability. While prospects depend on the efficacy of nucleoside analogs and partnerships, the risk of capital shortages and past failures seriously limit business growth.

NCNA (NuCana plc) Net earnings per share for the last 12 months history from 07/04/2022 to 11/17/2026
Mass-produced product of NuCana Corp

Investors assess the operational strength of assets through real earnings per share. For NuCana plc (NCNA), which develops innovative chemotherapy, this parameter is critical while awaiting drug commercialization. The TTM fundamental earnings per share trend excludes the impact of issuance, stripping the financial result of fluctuations in the number of shares. This metric measures the net efficiency of the business, revealing true profitability trends. This allows for the determination of the company's resilience to market shocks.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months